To sum up, the targeted inhibition of p65, LMP1, IKK, CDH6, Pim1, BST2, NEAT1, and the targeted activation of SIRT6, DLC-1, TNFAIP3, RERG, NKG2DLs in the targeted therapy of NPC could be a potential therapeutic strategy through the NF-κB pathway. Here, SIRT6 is linked to nasopharyngeal carcinoma.